- Home
- ALPS vs NRXS Comparison
ALPS vs NRXS Comparison
Compare ALPS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ALPS | NRXS |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.5M | 78.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | ALPS | NRXS |
|---|---|---|
| Price | $0.50 | $6.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 61.4K | ★ 73.9K |
| Earning Date | 07-24-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $0.45 | $2.20 |
| 52 Week High | $1.72 | $9.33 |
Technical Indicators
Market Signals| Indicator | ALPS | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 32.01 | 41.66 |
| Support Level | N/A | $6.29 |
| Resistance Level | $0.77 | $7.71 |
| Average True Range (ATR) | 0.04 | 0.36 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 18.59 | 12.00 |
Price Performance
Historical ComparisonAbout ALPS ALPS Group Inc Ordinary Share
ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).